top of page

June 2020 // Communication

Updated: Mar 19, 2021

Synendos Therapeutics received a prestigious European grant (SME Instrument Phase I, TWO-BIRDS project ) that helped the company to head towards clinical trials. The European commission is now reporting about the results and the perspectives to treat post-traumatic stress disorder (PTSD) and other neuropsychiatric diseases. Read the full article here.



Recent Posts

See All

January 2024 // Company & Communication

Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510. Synendos transitions to a clinical-stage biotech company developing innovative Endocanna

July 2023 // Communication

Synendos Therapeutics AG announces that co-founder and Scientific Advisor Board member, Professor Jürg Gertsch, presented groundbreaking new findings on an endocannabinoid transporter at the 10th Gord

Commenti


bottom of page